



**GENTIAN VIOLET,  
LEUCOGENTIAN VIOLET,  
MALACHITE GREEN,  
LEUCOMALACHITE GREEN,  
AND CI DIRECT BLUE 218**

VOLUME 129

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 22 February to 5 March 2021

LYON, FRANCE - 2022

IARC MONOGRAPHS  
ON THE IDENTIFICATION  
OF CARCINOGENIC HAZARDS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	<b>1</b>
<b>LIST OF PARTICIPANTS</b> .....	<b>3</b>
<b>PREAMBLE</b> .....	<b>7</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	<b>7</b>
1. Background.....	7
2. Objective and scope.....	8
3. Selection of agents for review .....	9
4. The Working Group and other meeting participants.....	9
5. Working procedures.....	11
6. Overview of the scientific review and evaluation process .....	12
7. Responsibilities of the Working Group.....	14
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	<b>15</b>
1. Exposure characterization .....	15
2. Studies of cancer in humans.....	18
3. Studies of cancer in experimental animals.....	23
4. Mechanistic evidence .....	26
5. Summary of data reported.....	29
6. Evaluation and rationale.....	30
References.....	35
<b>GENERAL REMARKS</b> .....	<b>39</b>
<b>GENTIAN VIOLET AND LEUCOGENTIAN VIOLET</b> .....	<b>43</b>
1. Exposure Characterization .....	43
1.1 Identification of the agent .....	43
1.2 Production and use.....	45
1.3 Methods of detection and quantification .....	47
1.4 Occurrence and exposure.....	52
1.5 Regulations and guidelines .....	54

2. Cancer in Humans .....	57
3. Cancer in Experimental Animals .....	57
3.1 Gentian violet .....	57
3.2 Leucogentian violet .....	67
3.3 Evidence synthesis for cancer in experimental animals .....	67
4. Mechanistic Evidence .....	68
4.1 Absorption, distribution, metabolism, and excretion .....	68
4.2 Evidence relevant to key characteristics of carcinogens .....	69
4.3 Other relevant evidence .....	78
4.4 Data relevant to comparisons across agents and end-points .....	78
5. Summary of Data Reported .....	81
5.1 Exposure characterization .....	81
5.2 Cancer in humans .....	82
5.3 Cancer in experimental animals .....	82
5.4 Mechanistic evidence .....	82
6. Evaluation and Rationale .....	83
6.1 Cancer in humans .....	83
6.2 Cancer in experimental animals .....	83
6.3 Mechanistic evidence .....	83
6.4 Overall evaluation .....	83
6.5 Rationale .....	83
References .....	83
<b>MALACHITE GREEN AND LEUCOMALACHITE GREEN .....</b>	<b>91</b>
1. Exposure Characterization .....	91
1.1 Identification of the agent .....	91
1.2 Production and use .....	93
1.3 Methods of detection and quantification .....	95
1.4 Occurrence and exposure .....	100
1.5 Regulations and guidelines .....	104
2. Cancer in Humans .....	105
3. Cancer in Experimental Animals .....	105
3.1 Malachite green .....	105
3.2 Leucomalachite green .....	112
3.3 Evidence synthesis for cancer in experimental animals .....	115
4. Mechanistic Evidence .....	115
4.1 Absorption, distribution, metabolism, and excretion .....	115
4.2 Evidence relevant to key characteristics of carcinogens .....	116
4.3 Data relevant to comparisons across agents and end-points .....	136
5. Summary of Data Reported .....	138
5.1 Exposure characterization .....	138
5.2 Cancer in humans .....	138
5.3 Cancer in experimental animals .....	139
5.4 Mechanistic evidence .....	139

6. Evaluation and Rationale. ....	141
6.1 Cancer in humans. ....	141
6.2 Cancer in experimental animals. ....	141
6.3 Mechanistic evidence. ....	141
6.4 Overall evaluation. ....	141
6.5 Rationale. ....	141
References. ....	141
<b>CI DIRECT BLUE 218. ....</b>	<b>151</b>
1. Exposure Characterization. ....	151
1.1 Identification of the agent. ....	151
1.2 Production and use. ....	153
1.3 Methods of detection and quantification. ....	154
1.4 Occurrence and exposure. ....	155
1.5 Regulations and guidelines. ....	156
2. Cancer in Humans. ....	157
3. Cancer in Experimental Animals. ....	157
3.1 Mouse. ....	157
3.2 Rat. ....	162
3.3 Evidence synthesis for cancer in experimental animals. ....	163
4. Mechanistic Evidence. ....	163
4.1 Absorption, distribution, metabolism, and excretion. ....	163
4.2 Evidence relevant to key characteristics of carcinogens. ....	164
4.3 Data relevant to comparisons across agents and end-points. ....	166
5. Summary of Data Reported. ....	166
5.1 Exposure characterization. ....	166
5.2 Cancer in humans. ....	167
5.3 Cancer in experimental animals. ....	167
5.4 Mechanistic evidence. ....	167
6. Evaluation and Rationale. ....	168
6.1 Cancer in humans. ....	168
6.2 Cancer in experimental animals. ....	168
6.3 Mechanistic evidence. ....	168
6.4 Overall evaluation. ....	168
6.5 Rationale. ....	168
References. ....	168
<b>LIST OF ABBREVIATIONS. ....</b>	<b>173</b>
<b>ANNEX 1. Supplementary material for Section 4, Mechanistic evidence. ....</b>	<b>175</b>
<b>SUMMARY OF FINAL EVALUATIONS. ....</b>	<b>177</b>

